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Waiting time to radiotherapy as a prognostic
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ABSTRACT
Objective: To evaluate the effect of waiting time (WT) to radiotherapy (RT) on overall survival (OS) of glioblastoma (GBM) patients as a
reliable prognostic variable in Brazil, a scenario of medical disparities. Method: Retrospective study of 115 GBM patients from two
different health-care institutions (one public and one private) in Brazil who underwent post-operative RT. Results: Median WT to RT was 6
weeks (range,1.3-17.6). The median OS for WT# 6 weeks was 13.5 months (95%CI , 9.1-17.9) and for WT. 6 weeks was 14.2 months (95%CI,
11.2-17.2) (HR 1.165, 95%CI 0.770-1.762; p = 0.470). In the multivariate analysis, the variables associated with survival were KPS (p, 0.001),
extent of resection (p = 0.009) and the adjuvant treatment (p = 0.001). The KPS interacted with WT to RT (HR 0.128, 95%CI 0.034-0.476;
p = 0.002), showing that the benefit of KPS on OS depends on the WT to RT. Conclusion: No prognostic impact of WT to RT could be detected
on the OS. Although there are no data to ensure that delays to RT are tolerable, we may reassure patients that the time-length to initiate
treatment does not seem to influence the control of the disease, particularly in face of other prognostic factors.
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RESUMO
Objetivo: Avaliar o efeito do tempo de espera (TE) até radioterapia na sobrevida global de pacientes com glioblastoma como um fator
prognóstico confiável. Método: Estudo retrospectivo de 115 pacientes com glioblastoma, que foram submetidos à radioterapia pós-
operatória, em dois serviços diferentes no Brasil (um público e outro privado). Resultados: Mediana de TE para radioterapia foi de 6
semanas (variação, 1,3-17,6). A mediana de sobrevida para TE # 6 semanas foi de 13,5 meses (IC95%, 9,1-17,9) e para TE . 6 semanas foi
de 14,2 meses (IC95%, 11,2-17,2) (HR 1,165, 0,770-1,762; p = 0,470). Na análise multivariada, as variáveis associadas à sobrevida foram
perfomance status (p , 0,001), extensão da ressecção (p = 0,009) e tratamento adjuvante (p = 0,001). Conclusão: Não se observou
impacto prognóstico para TE até a radioterapia na sobrevida. Diante de outros fatores prognósticos, é possível assegurar de que o espaço
de tempo até a radioterapia não parece influenciar o controle da doença.
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The investigation of the impact of delaying radiotherapy
(RT) on the outcomes of various tumors - particularly breast
and head-and-neck - has generated no clear results. Never-
theless, there is considerable evidence to support that delay
of RT may have an adverse effect on patients’ outcomes1,2,3.
Glioblastoma (GBM) patients have been the subject of
many clinical investigations aiming to determine the effects
of waiting time (WT) for initiation of RT4,5,6,7,8,9,10,11,12,13,14,15,16.
Much of the interest in seeking a presumable negative
impact of the delay for this kind of tumor is based on its
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median overall survival (OS) that rarely exceeds 14 months17.
So far, available reports are still controversial, although most
of the data show no evidence to justify delaying RT beyond
6 weeks18.
Due to multiple factors, Brazil faces a shortage of RT
resources and, according to the most recent data, only
65.9% of the RT demand is met. Nationwide and regardless
of tumor type, the mean WT to RT is 113.4 days (almost 4
months) and, barely 15% of the patients initiate RT before
4 weeks following diagnosis19,20. This unfortunate reality
and the well-known Brazilian medical disparities have pro-
vided the perfect scenario to evaluate a cohort of GBM
patients regarding the effect of RT delay on survival.
Therefore, this study aimed to evaluate the impact of WT
to RT as a reliable prognostic variable in 115 GBM patients
from two different health-care institutions in the country.
METHOD
We conducted a retrospective study of adult patients
($ 18 years old) who had a newly diagnosed GBM according
to World Health Organization classification (WHO, 2007)21
and were treated with RT after surgery, between January
2003 and December 2011, from two Brazilian hospital data-
bases: Hospital Israelita Albert Einstein (HIAE), a private-prac-
tice service, and Hospital São Paulo - Universidade Federal de
São Paulo (HSP-UNIFESP), a public healthcare center.
The medical records of 132 patients were reviewed in
order to obtain relevant data: gender, age at diagnosis,
Karnofsky Performance Status (KPS), date of first symptom,
date of death, date and extent of neurosurgery based on
postoperative CT or MRI (within the first 48 hours), and
characteristics of RT and chemotherapy. We did not invest-
igate the causes of delay in RT. We excluded 17 patients due
to missing data: 3 had no information on the extent of resec-
tion, 8 had no information about the adjuvant treatment
and, 6 because no starting date of RT was reported. The
remaining 115 patients (76 from HSP-UNIFESP and 39 from
HIAE) formed our study cohort.
Patients underwent neurosurgical procedure aiming for
maximal safe resection whenever possible. All analyzed sub-
jects underwent 3D localized external beam RT using treat-
ment planning systems based on the contrast-enhancing
lesion shown on pre-operative contrast-enhanced TC and/
or T2/FLAIR sequence MRI. For the purpose of this study,
we recorded only the maximum dose actually delivered to
the tumor bed at the time of the initial RT, typically 60 Gy
in 30 fractions.
At HSP-UNIFESP, before 2009, the patients received
Carmustine (BCNU) 200 mg/m2 at 6 weeks intervals starting
6 weeks after RT. Since 2009, Temozolomide (TMZ) became
available and patients could be treated according to
the EORTC-NCIC protocol22. At HIAE, all patients were
treated according to EORTC-NCIC protocol22. The patients
who underwent concomitant and adjuvant TMZ were
categorized as “RT concurrent with chemotherapy”; those
who received BCNU were defined as “RT and sequencing
chemotherapy”.
The ethics review board of both institutions approved
this study.
Statistical analysis
Data were described using absolute and relative frequen-
cies for categorical data. Quantitative data were described
using median and range, due to skewness. OS was calculated
from time of diagnosis until death or last follow up (cut-off
date October 17, 2012).
The waiting time between first symptoms and neuro-
surgery (WT to NS) was calculated using the estimated date
of first symptoms to the day of the neurosurgical interven-
tion (biopsy or surgical resection) and was categorized based
on its median. The WT to RT was calculated in weeks
between the date of the first neurosurgery and the starting
date of RT. We categorized WT to RT based on its median
into two groups: RT delay# 6 weeks (WT# 6) and RT delay
. 6 weeks (WT . 6). Data from the groups were compared
by using Pearson’s Chi-square or Fisher’s test for categorical
data and Mann-Whitney U-test for quantitative variables. A
p-value of , 0.05 was considered significant.
Survival curves were constructed according to the
Kaplan-Meier method and compared between groups using
log-rank test to explore relationships between well-recog-
nized prognostic factors (age, KPS, extent of resection, adjuv-
ant treatment) and survival in the univariate analysis. Data
from two diverse institutions were evaluated and we
observed a significant association between WT to RT and
institution. In order to avoid multicolinearity, only the WT
to RT was explored as a prognostic factor.
A conditional stepwise proportional hazard analysis (Cox-
regression model) was used to identify independent predic-
tors of survival. The variables that achieved a p-value , 0.1
in the univariate analysis were included in the multivariate
model. The WT to RT variable was retained in the model
because it is the object of the study, although not significant
in the univariate analysis. In addition, we explored the inter-
actions among WT to RT and other variables, and the multi-
variate model was adjusted to include only significant
interactions.
The statistical analysis was performed using the statist-
ical softwares R (R Core Team (2012). R: A language and
environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0,
URL http://www.R-project.org/) and SPSS (SPSS Inc.
Released 2008. SPSS Statistics for Windows, Version 17.0.
Chicago: SPSS Inc.).
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RESULTS
For the entire cohort, the median age was 57 years
(range, 18-83). There were 44 females and 71 males (ratio
1:1.6). The median intervals were: WT to NS 6.7 weeks
(range, 0.14-1435) and WT to RT 6 weeks (range, 1.3-17.6).
Median final RT dose was 60 Gy (range, 10-66). Median fol-
low-up time was 12.9 months (range, 1.1-58) and estimated
OS was 14.1 months (95%CI, 11.6-16.6).
The median interval for WT # 6 group was 4.1 weeks
(range, 1.3-6) and 8.6 weeks (range, 6.1-17.6) for the WT . 6
group. Table 1 shows patients’ demographics, clinical and
treatment characteristics as a function of the WT to RT
interval.
We did not observe a deleterious effect of longer WT
to RT on survival, as shown in Figure 1. The median OS for
WT # 6 was 13.5 months (95%CI, 9.1-17.9) and for WT . 6
was 14.2 months (95%CI, 11.2-17.2) (HR 1.165, 95%CI 0.770-1.762;
p = 0.470). We observed a significantly better OS for age , 50
years, KPS $ 70%, final total RT dose $ 60 Gy and adjuvant
treatment including any chemotherapy (Table 2).
We explored the impact of clinical characteristics and
adjuvant treatment on OS using a Cox regression model
(Table 3). The only significant clinical variable associated
with survival was KPS (p , 0.001). Regarding treatment
characteristics, the extent of resection (p = 0.009) and the
adjuvant treatment (p = 0.001) had also an association
with OS.
We also evaluated the potential interactions between
patient’s characteristics and WT to RT. The only variable
that interacted with WT to RT was KPS. Figure 2 shows that
the effect of KPS on OS depends on the WT to RT.
Table 1. Demographics, clinical and treatment characteristics of patients according to the WT to RT interval.
WT # 6 WT . 6
p
61 (53%) 54 (47%)
Gender 0.159
Male 34 (55.7%) 37 (68.5%)
Age (years) 0.071
, 50 14 (23.0%) 21 (38.9%)
$ 50 47 (77.0%) 33 (61.1%)
KPS (%) 0.423
, 70 11 (23.4%) 9 (17.0%)
$ 70 36 (76.6%) 44 (83.0%)
Neurosurgery (extent of resection) 0.115
Biopsy 8 (13.1%) 3 (5.6%)
Partial 20 (32.8%) 27 (50.0%)
Gross-total 33 (54.1%) 24 (44.4%)
WT to NS 0.021
# 6.7 weeks 33 (61.1%) 21 (38.9%)
. 6.7 weeks 21 (38.9%) 33 (61.1%)
Final total RT dose (Gy) 0.050
, 60 15 (26.3%) 23 (44.2%)
$ 60 42 (73.7%) 29 (55.8%)
Adjuvant treatment 0.004
RT Only 13 (21.3%) 15 (27.8%)
RT and sequencing chemotherapy 11 (18.0%) 22 (40.7%)
RT concurrent with chemotherapy 37 (60.7%) 17 (31.5%)
WT: Waiting time; RT: Radiotherapy; KPS: Karnofsky performance status; WT to NS: Waiting time between first symptoms and neurosurgery.
Figure 1. Overall survival according to waiting time from
neurosurgery to radiotherapy for glioblastoma patients
(p = 0.470).
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DISCUSSION
In this study of 115 GBM Brazilian patients, delaying RT
longer than 6 weeks did not affect the OS and may not be
credited as a reliable prognostic factor (HR 1.323, 95%CI
0.731-2.393; p = 0.355). The problem of delaying RT in
GBM treatment has been debated more extensively because
of the fast-growing nature of this tumor13 and its ability to
invade surrounding tissues, making tumor control much
more difficult over time23,24. To date, data published on this
theme are considered controversial, partially because prior
studies presented diverse methodologies and patients with
different characteristics4,5,6,7,8,9,10,11,12,13,16,18.
In line with our data, previous reports failed in detecting
any disadvantage in delaying RT. In 2000, Do et al.4 in
the first published attempt to address the issue, reported
Table 2. Overall survival according to patients’ characteristics.
Median survival time in months (95%CI) HR (95%CI) p
Age (years) 0.032
, 50 18.8 (15.0-22.6)
$ 50 12.5 (10.1-14.9) 1.637 (1.042-2.571)
KPS (%) , 0.001
, 70 9.0 (5.1-12.9)
$ 70 15.8 (13.3-18.2) 0.377 (0.220-0.648)
Neurosurgery (extent of resection) 0.096
Biopsy 11.5 (9.7-13.3)
Partial 15.7 (11.3-20.1) 0.613 (0.297-1.264)
Gross-total 14.1 (11.8-16.4) 0.464 (0.224-0.962)
WT to NS 0.295
# 6.7 weeks 15.7 (12.7-18.8)
. 6.7 weeks 12.9 (10.0-15.7) 1.252 (0.822-1.908)
Final total RT dose (Gy) 0.042
, 60 11.0 (8.2-13.7)
$ 60 16.2 (13.5-19.0) 0.641 (0.418-0.985)
Adjuvant Treatment , 0.001
RT Only 8.1 (5.2-11.0)
RT and sequencing chemotherapy 15.8 (13.8-17.7) 0.282 (0.163-0.487)
RT concurrent with chemotherapy 17.7 (15.2-20.2) 0.231 (0.136-0.394)
WT: Waiting time; RT: Radiotherapy; KPS: Karnofsky performance status; WT to NS: Waiting time between first symptoms and neurosurgery; HR: Hazard
ratio; CI: confidence interval.
Table 3. Multivariate analysis.
HR (95%CI) p
WT to RT 0.355
# 6 weeks 1
. 6 weeks 1.323 (0.731-2.393)
Age (years) 0.837
, 50 1
$ 50 0.939 (0.518-1.705)
KPS (%) , 0.001
# 70 1
, 70 6.794 (2.799-16.49)
Neurosurgery (extent of resection)*
Gross-total 1
Partial 1.174 (0.712-1.937) 0.530
Biopsy 4.382 (1.703-11.278) 0.002
Final total dose of RT (Gy)
$ 60 1
, 60 1.176 (0.708-1.954) 0.531
Adjuvant treatment†
RT concurrent with chemotherapy 1
RT and sequencing chemotherapy 1.184 (0.651-2.154) 0.580
RT Only 3.259 (1.713-6.202) , 0.001
*Global p-value = 0.009; †Global p-value = 0.001. WT: Waiting time; RT: Radiotherapy; KPS: Karnofsky performance status; HR: Hazard ratio; CI: Confidence
interval.
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no detrimental impact on survival when longer intervals
between neurosurgery and RT occurred (HR 1.00, 95%CI
0.99-1.02; p = 0.09). The main limitation of that study was
the inclusion in the same cohort of grade 3 and grade 4 glio-
mas, which are currently known to present different beha-
viors. Other authors6,8,9,10,12, already working in the era of
TMZ concomitant with RT, support the result of no signific-
ant effect of longer WT to RT on OS in GBM patients.
Likewise, using a huge cohort extracted from patients
enrolled in the Radiation Therapy Oncology Group (RTOG)
protocols, and accounting for close to 3,000 GBM patients,
Blumenthal et al.7 found no reduction in survival associated
with RT delay, within a temporal limit of 6 weeks.
Remarkably, median survival was significantly greater for
those with the longest WT to RT (. 4 weeks) than the group
presenting a shorter WT to RT (# 2 weeks) (p , 0.001).
Some authors14,15,16 reported comparable unexpected results
when patients submitted to a longer WT to RT had also a
longer survival. Similarly, we observed the same tendency
for better survival for WT . 6 (median 14.2 months),
although not significant (p = 0.470). These patients (WT . 6)
had no remarkable advantage regarding age, KPS and, treat-
ment characteristics if compared to the WT # 6 group. No
clear radiobiological mechanisms can be proposed to explain
such phenomenon, although physician selection bias of poor
performance patients has already been pointed out as an
alternative reason7. Some authors corroborate this hypothesis
suggesting that better performing patients wait longer to
RT5,9,16,18. In our cohort, the only clinical variable that interacted
with WT to RT was KPS (HR 0.128, 95%CI 0.034-0.476; p =
0.002), showing that the benefit of KPS on OS depends on
the WT to RT. In fact, as depicted in Figure 2, when patients
with KPS , 70% were submitted to RT in # 6 weeks they
showed the worst OS (6.4 months; range, 5.4-7.3). This is a par-
ticular potential bias for some retrospective studies published
so far, since poor prognosis patients seem to be first in line
for treatment.
Three studies reached conclusions opposing our data.
Irwin et al.5 were the first to report a negative impact of
the delay in RT for GBM patients. The study reported a
mean WT to RT of 5.01 weeks and, each additional week
of delay increases the risk of death by 8.9% (HR 1.089, 95%
CI 1.020-1.161; p = 0.010). The major limitations of the study
were the inclusion of two pathology subtypes (grade 3 and 4
gliomas) and the great variability of RT dose used. Only
30.8% of the patients received a final dose of $ 60 Gy and
some patients had their RT dose chosen based upon the per-
formance status. In addition, in their multivariate analysis,
the RT dose was found to positively influence survival. Our
patients were more homogeneous since the final total RT
dose between the groups was similar (p = 0.05), and all sub-
jects underwent the same RT technique over the period, tar-
geting a final dose of 60 Gy. As for Valduvieco et al.11 study,
107 GBM patients submitted to a complete surgical resec-
tion were analyzed and showed WT to RT # 6 weeks as
an independent survival predictor (HR 0.42, 95%CI 0.06-0.96;
p = 0.043). However, some limitations must be pointed out:
first, the WT to RT cut-off of 6 weeks was chosen based on
historical data and not on its median, causing an imbalance
between the groups; second, the restricted inclusion criterion
of completed resected patients may limit the generalizability
of their results; third, significantly more patients (86%,
Figure 2. Median estimated survival time according to WT to RT and KPS.
108 Arq Neuropsiquiatr 2015;73(2):104-110
p = 0.0014) in the RT delay# 6 weeks subgroup received some
kind of chemotherapy, creating a potential bias since the use
of chemotherapy (TMZ or nitrosureas) was associated with
longer survival in the multivariate analysis. In our study, we
decided to use the TMZ concomitant with RTas the reference
value in the multivariate analysis, aiming to minimize the
interpretation bias and we did not detect any advantage when
comparing TMZ to the use of sequential chemotherapy
(BCNU). In addition, the use of adjuvant chemotherapy
(BCNU or TMZ) was equivalently allocated between our sub-
groups (WT # 6 weeks 78% x WT . 6 weeks 71%). Lastly, in
an impressive cohort of 345 TMZ treated GBM patients,
Spratt et al.16 demonstrated a detrimental effect of delaying
RT greater than 6 weeks (HR 3.76, 95%CI 1.01-14.57; p = 0.05)
for a subset of patients with known O6-methylguanine DNA
methyltransferase (MGMT) status; although only 45.8% of their
cohort had MGMT status. No detrimental impact on OS was
found (HR 1.68, 95%CI 0.94-3.06; p = 0.08) when the entire
cohort was analyzed, including unknown MGMT status
patients.
Although we could not retrieve the causes of delaying RT,
there is an interest in understanding what would justify the
WTs to RT since it is well known that the delay may causes
distress and sometimes impact the quality of life due to per-
sisting symptoms24. Many authors argue that the inevitable
reason for increasing WTs is the failure to reconcile RT to its
demand, creating a continuous imbalance1,2,3. Even developed
countries face this problem25,26,27,28,29, which may be even more
profound in primarily government funded health care systems.
In Brazil, despite recent government efforts19, the scenario is
still worrisome and the growing demand for RT has created
an inefficient system where only 65.9% of the demand is met
and long WTs are commonplace with a median WT to RT
of 113.4 days (almost 4 months)19,20, regardless of tumor type.
Indeed, our data reveals a median interval for WT . 6 group
of 8.6 weeks, but in this subset, WTas long as 17.6 weeks could
be found. Another relevant aspect of the situation is the
lengthy admission process into the health care system, which
may be reflected in the WT to NS (median of 6.7 weeks).
Most patients (61.1%) who waited longer for neurosurgery
(. 6.7 weeks) also had a longer WT to RT (. 6 weeks)
(p = 0.021). This may be seen as an indication of failure to
obtain adequate care when early symptoms first occur. We
are aware though that the date of the first symptom may be
a source of error, which may add bias to these results.
Our study has some limitations. First, its retrospective
nature may subject the study to common drawbacks such
as patient uncontrolled selection bias and missing data.
Thus, our results may not apply in other temporal and spa-
tial contexts. To minimize the selection bias we controlled
our analysis considering well-known prognostic factors. It
should be noted that a randomized controlled trial to finally
elucidate this important debate might not be possible due to
ethical issues1,2,3,18. Second, we included patients from two
diverse health-care institutions and the WT to RT was sig-
nificantly related to the institution. However, we must
emphasize that to avoid multicolinearity, only the WT to
RT was explored as a prognostic factor. Additionally, we
reported before that the medical assistance scenario was
not an independent predictor of survival30 and, by electing
patients from two diverse healthcare settings, we aimed to
reflect the Brazilian reality. Third, we included only patients
submitted to RT at some point of their treatment. Lastly, the
long time period of the study may have affected the final
results due to the diverse adjuvant treatment approaches.
To minimize this potential bias, as stated earlier, we decided
to use the RT concurrent with chemotherapy as the ref-
erence treatment in the multivariate analysis and observed
that no advantage was found when comparing this regimen
to the use of sequencing chemotherapy (BCNU) (HR 1.184, 95%CI
0.651-2.154; p = 0.580). Therefore, it is unlikely that the addi-
tion of TMZ in the treatment arsenal caused any bias to
the outcome of our sample.
Our results echo much of the previous published data
and no prognostic impact of WT to RT could be detected
on the survival of GBM patients. Although there are no data
to ensure that delays to RT are tolerable, we may reassure
patients that the control of the disease does not seem to
be influenced by the time-length to initiate treatment, par-
ticularly when we consider the power of other prognostic
factors. In any case, we should not lose sight of the increas-
ing imbalance between the RT demand and supply and the
imperative need of a carefully planned strategy by the
healthcare system to handle this challenge.
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